List of Excipients in Branded Drug LUMIFY PRESERVATIVE FREE EYE DROPS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	LUMIFY PRESERVATIVE FREE EYE DROPS	brimonidine tartrate	24208-538	BORIC ACID
Bausch & Lomb Incorporated	LUMIFY PRESERVATIVE FREE EYE DROPS	brimonidine tartrate	24208-538	CALCIUM CHLORIDE
Bausch & Lomb Incorporated	LUMIFY PRESERVATIVE FREE EYE DROPS	brimonidine tartrate	24208-538	GLYCERIN
Bausch & Lomb Incorporated	LUMIFY PRESERVATIVE FREE EYE DROPS	brimonidine tartrate	24208-538	HYDROCHLORIC ACID
Bausch & Lomb Incorporated	LUMIFY PRESERVATIVE FREE EYE DROPS	brimonidine tartrate	24208-538	POTASSIUM CHLORIDE

LUMIFY Preservative-Free Eye Drops: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 21, 2026

LUMIFY Preservative Free is an ophthalmic redness-relief product containing brimonidine tartrate 0.025%. Its commercial differentiation depends less on novel active-ingredient chemistry than on preservative-free delivery, packaging, ocular tolerability, stability, and consumer convenience. The core excipient system is a conventional ophthalmic buffer and tonicity platform, while the principal defensible asset is likely the combination of formulation, container-closure system, and product presentation.

What is LUMIFY Preservative Free?

LUMIFY Preservative Free is a topical ophthalmic solution marketed by Bausch + Lomb for temporary reduction of ocular redness. The active ingredient is brimonidine tartrate at a concentration equivalent to brimonidine 0.025% [1].

Attribute	Product profile
Brand	LUMIFY Preservative Free
Active ingredient	Brimonidine tartrate
Strength	0.025%
Dosage form	Sterile ophthalmic solution
Therapeutic category	Ocular redness reliever
Route	Topical ophthalmic
Preservative status	Preservative-free
Sponsor/marketer	Bausch + Lomb
Primary commercial use	Temporary reduction of ocular redness
Regulatory pathway	FDA-regulated ophthalmic drug product

Brimonidine is an alpha-2 adrenergic receptor agonist. At the LUMIFY concentration, it produces selective vasoconstriction of conjunctival blood vessels with a lower concentration than prescription brimonidine products used for glaucoma.

The preservative-free version targets consumers who use redness-relief drops regularly, have ocular-surface sensitivity, wear contact lenses, or prefer single-use packaging.

What excipients are used in LUMIFY Preservative Free?

The publicly identified excipient platform consists of boric acid, sodium borate, sodium chloride, and water for injection or purified ophthalmic-grade water, depending on the applicable product presentation and labeling [1, 2].

Excipient class	Likely function in the product	Commercial importance
Boric acid	Buffering and pH control; contributes to tonicity	Supports ocular comfort and chemical stability
Sodium borate	Buffering and pH control	Maintains formulation pH during shelf life
Sodium chloride	Tonicity adjustment	Reduces stinging associated with hypotonic or hypertonic solutions
Water for injection	Vehicle	Provides sterile aqueous delivery medium
Container-closure system	Sterility preservation after manufacture	Replaces the antimicrobial role normally supplied by preservatives

The formulation does not rely on a conventional antimicrobial preservative such as benzalkonium chloride, polyquaternium-1, chlorobutanol, or stabilized oxychloro complex. That shifts the product-development burden from chemical preservation to aseptic processing and package integrity.

Why are borate excipients commercially important?

Borate systems are widely used in ophthalmic products because they can provide pH control with relatively simple formulation architecture. For LUMIFY, the buffer system must balance several variables:

• Brimonidine chemical stability.
• Ocular comfort.
• Compatibility with the container.
• Control of solution pH.
• Maintenance of tonicity.
• Compatibility with sterilization and filling operations.

The excipient system is therefore commercially relevant even though the individual ingredients are inexpensive and widely available. The value lies in the selected concentrations, pH range, manufacturing process, and container-closure combination.

How does preservative-free packaging change the formulation strategy?

Preservative-free ophthalmic products must control microbial contamination without relying on an antimicrobial excipient. They generally use one of three approaches:

1. Single-dose vials.
2. Multidose bottles with a non-return valve or sterile-filtering dispensing system.
3. Multidose systems with specialized bottle geometry and microbial-barrier components.

The packaging decision affects product cost, dosing accuracy, waste, convenience, and intellectual-property exposure.

Packaging model	Advantages	Commercial limitations
Single-dose vial	Strong sterility control; simple preservative-free claim	Higher packaging cost; more plastic waste; less convenient for repeated use
Conventional multidose bottle	Familiar consumer format; lower unit cost	Greater contamination risk after opening
Preservative-free multidose dispenser	Consumer convenience with reduced contamination risk	Higher device cost; device validation and freedom-to-operate issues
Unit-dose strip or ampoule	Suitable for travel and sampling	Less attractive for routine daily use

The package is part of the product strategy, not a secondary component. For a preservative-free eye drop, the container-closure system can be as important as the liquid formulation.

What are the commercial opportunities for LUMIFY excipients?

The largest opportunities are in excipient optimization, delivery hardware, and manufacturing efficiency rather than replacement of the active ingredient.

Low-irritation formulation platforms

A preservative-free brimonidine product can compete on comfort and ocular-surface tolerability. Opportunities include:

• Optimizing borate concentration to reduce stinging.
• Adjusting osmolality toward the tear-film range.
• Controlling pH to improve comfort without compromising brimonidine stability.
• Evaluating alternative buffering systems.
• Reducing extractables and leachables from the package.
• Improving drop size and dosing consistency.

These opportunities are relevant to both branded line extensions and generic or private-label products.

Preservative-free multidose delivery

A multidose preservative-free bottle can support a higher retail price than a conventional preserved product. Value drivers include:

• Easier repeated dosing.
• Lower handling burden than unit-dose vials.
• Better consumer acceptance among frequent users.
• Reduced exposure to ocular-surface preservatives.
• Potential differentiation for contact-lens users, subject to labeling and compatibility requirements.

Device companies with sterile dispensing systems, non-return valves, filter membranes, or antimicrobial package barriers have potential licensing opportunities.

Premium formulation extensions

Potential line extensions could include:

• Preservative-free brimonidine with enhanced comfort positioning.
• Larger-volume bottles for frequent users.
• Travel-size unit-dose presentations.
• Combination products with lubricating functionality, subject to FDA requirements.
• Products designed for patients with dry-eye symptoms who also seek redness relief.
• Pediatric or sensitivity-focused packaging, where supported by clinical and regulatory data.

A combination with a lubricant would require careful evaluation because adding polymers, surfactants, or viscosity modifiers could change ocular residence time, drop feel, preservative-free sterility requirements, and regulatory classification.

What patents protect LUMIFY Preservative Free?

The key patent categories are likely to include formulation, use, dosage, packaging, and manufacturing claims. Public product labeling does not establish a complete list of patents protecting every LUMIFY Preservative Free presentation.

Potential protection category	Relevant subject matter	Strategic value
Active-ingredient claims	Brimonidine tartrate chemistry	Limited because brimonidine is an established molecule
Concentration claims	Brimonidine at 0.025% for ocular redness	Potentially relevant to product differentiation
Method-of-use claims	Temporary reduction of ocular redness	May support branded positioning
Formulation claims	Buffer, pH, tonicity, stability, and excipient ranges	Potentially relevant to product-specific competition
Packaging claims	Preservative-free multidose or unit-dose delivery	Potentially important for commercial substitution
Manufacturing claims	Aseptic filling, sterilization, and container preparation	May create process barriers
Trade secrets	Exact excipient concentrations, process parameters, and packaging controls	Can remain valuable after published patent rights expire

The strongest defensible position would typically be a coordinated portfolio covering the formulation and the delivery system rather than relying on a single claim directed to a common excipient.

What is the Orange Book status of LUMIFY?

The FDA Orange Book is principally relevant to approved prescription and certain approved drug applications for which therapeutic-equivalence determinations and listed patents apply [3]. LUMIFY is marketed as an over-the-counter ophthalmic product, and the Orange Book is not the sole source for determining all commercial or intellectual-property constraints affecting the product.

The relevant regulatory questions are:

• Whether the specific presentation is associated with an approved NDA or supplemental NDA.
• Whether the product is marketed under an OTC monograph pathway or an approved application.
• Whether any patents are listed for the applicable application.
• Whether a competing product would proceed through an ANDA, an OTC monograph route, or another FDA pathway.
• Whether the competitor would need to establish equivalence for the finished dosage form and delivery system.

An Orange Book listing, if applicable to a specific application, would not necessarily capture device patents, packaging rights, trademarks, manufacturing know-how, or patents assigned to affiliates or suppliers.

When does LUMIFY lose exclusivity?

There is no single exclusivity date that determines the end of LUMIFY’s commercial protection. Several rights operate independently:

Exclusivity or protection type	Effect on competition
FDA marketing exclusivity	Can delay certain competing applications where applicable
Active-ingredient patent rights	May restrict products using protected chemistry
Formulation patents	May restrict substantially similar liquid compositions
Method-of-use patents	May affect labeling or use claims
Device and packaging patents	May restrict use of a particular preservative-free dispenser
Trademark rights	Prevent confusingly similar branding but do not block unbranded competition
Trade secrets	May preserve manufacturing advantages without creating a formal market-exclusivity period

Because brimonidine is an established active ingredient, competition is more likely to focus on formulation, labeling, packaging, and consumer brand strength than on basic molecule exclusivity.

What Paragraph IV challenges could affect LUMIFY?

A Paragraph IV certification is relevant when a sponsor seeks approval of an ANDA referencing an approved drug application and challenges listed patents as invalid, unenforceable, or not infringed [4]. Its relevance to LUMIFY depends on the regulatory basis and patent listings associated with the specific reference product.

Potential challenger arguments could target:

• Lack of novelty for a low-concentration brimonidine solution.
• Obviousness of combining brimonidine with borate buffer and sodium chloride.
• Non-infringement based on different excipient concentrations.
• Use of a different preservative-free package.
• Use of a different pH or osmolality range.
• Absence of infringement because the competing product carries a narrower label.

The commercial outcome would depend on the scope of any listed claims. A broad formulation claim could create greater litigation exposure than a narrow package claim because competitors may design around a package while preserving the same active concentration.

What generic entry risks exist for LUMIFY?

Generic-entry risk is moderate to high at the active-ingredient level and more variable at the product-system level.

High-risk factors

• Brimonidine tartrate is an established compound.
• The concentration is technically accessible to competing manufacturers.
• The liquid formulation uses common ophthalmic excipients.
• The product does not depend on a complex biological process.
• Multiple contract manufacturers can produce sterile ophthalmic solutions.

Lower-risk factors

• Preservative-free multidose packaging may require specialized technology.
• Sterility assurance and microbial ingress testing increase development costs.
• Drop-size consistency can be difficult to match.
• Device and package patents may restrict direct copying.
• Retail brand recognition may support premium pricing.
• FDA equivalence requirements extend beyond the liquid composition when the delivery system affects performance.

A competitor could enter first with a unit-dose product, even if it cannot replicate the branded multidose presentation. That would create price pressure while leaving some device-based differentiation intact.

How does LUMIFY compare with preserved redness-relief drops?

LUMIFY’s principal formulation advantage is the absence of a conventional preservative. Many competing redness-relief products use preservatives because they are packaged in multidose bottles. The comparison is therefore driven by use frequency, ocular-surface tolerance, package format, and price.

Factor	LUMIFY Preservative Free	Conventional preserved redness-relief drop
Active ingredient	Brimonidine 0.025%	May use different vasoconstrictors
Preservative exposure	None stated in the product formulation	Commonly present
Packaging complexity	Higher	Lower
Unit cost	Likely higher	Usually lower
Frequent-use positioning	Strong	More limited where preservative sensitivity is a concern
Device dependence	High	Moderate
Formulation differentiation	Buffer, tonicity, stability	Often centered on active ingredient and preservative system
Switching risk	Moderate	High because consumers can select from many products

Brimonidine also has a distinct commercial position compared with older vasoconstrictors. The branded claim architecture, concentration, and consumer familiarity can reduce direct price comparability with tetrahydrozoline or naphazoline products.

What FDA regulatory issues affect the excipient strategy?

FDA regulation of ophthalmic products emphasizes sterility, stability, container-closure integrity, particulate control, extractables and leachables, and microbiological quality [5, 6].

For LUMIFY Preservative Free, the main regulatory risks include:

• Failure of sterility assurance during filling.
• Microbial ingress after repeated opening.
• Inadequate container-closure integrity.
• Variation in drop volume.
• Excipient-driven changes in pH or osmolality during shelf life.
• Brimonidine degradation or adsorption to package components.
• Particulate contamination.
• Inadequate in-use stability.
• Inaccurate preservative-free labeling.
• Device changes that alter delivered dose.

A formulation change that appears minor from an excipient perspective can require comparative stability, compatibility, microbiological, and performance data. This creates regulatory friction for fast followers.

Which companies could challenge LUMIFY commercially?

The competitive field includes branded ophthalmic companies, generic drug manufacturers, OTC consumer-health companies, and ophthalmic-device suppliers.

Competitor type	Likely strategy
Generic ophthalmic manufacturers	Low-price brimonidine or redness-relief alternatives
Large OTC companies	Brand extensions and retail distribution
Specialty ophthalmic companies	Comfort-focused or preservative-free products
Device suppliers	Licensed multidose preservative-free dispensers
Contract manufacturers	Private-label unit-dose or multidose products
Lubricant brands	Products positioned for ocular-surface comfort and redness

The most credible threat is a product that matches the active concentration and consumer indication while offering a lower-cost package. A second threat is a preservative-free lubricant or hybrid product that captures consumers concerned about redness and ocular comfort but does not directly duplicate LUMIFY.

What licensing opportunities exist in the LUMIFY excipient ecosystem?

Licensing opportunities are concentrated in delivery technology and manufacturing capability.

Packaging and device licensing

Potentially valuable technologies include:

• Preservative-free multidose dispensers.
• One-way valve systems.
• Sterile-filtering dispensing tips.
• Low-dead-volume bottles.
• Drop-size control components.
• High-barrier polymer containers.
• Automated aseptic filling systems.

Excipient and formulation licensing

The commercial value of a formulation license would depend on whether it delivers measurable performance improvements, such as:

• Longer chemical shelf life.
• Better comfort.
• Lower drop volume.
• Reduced container adsorption.
• Improved stability after opening.
• Compatibility with a wider range of packaging materials.

Common excipients alone are unlikely to command strong licensing economics. Proprietary concentration ranges, validated manufacturing conditions, or integrated package-formulation systems have greater value.

What manufacturing and intellectual-property barriers exist?

The primary manufacturing barrier is sterile ophthalmic production, not ingredient sourcing. Brimonidine tartrate, boric acid, sodium borate, sodium chloride, and pharmaceutical-grade water are generally available from multiple suppliers. The more difficult requirements are:

• Validated aseptic processing.
• Sterile filtration where appropriate.
• Container-closure integrity.
• Low particulate levels.
• Consistent drop formation.
• Microbial ingress control.
• Stable filling and capping operations.
• Compliance with ophthalmic current good manufacturing practice requirements.

The strongest manufacturing moat may arise from process know-how and package qualification. Those assets can reduce batch failures and shorten regulatory review for manufacturing changes.

What is the revenue exposure for Bausch + Lomb?

Bausch + Lomb does not generally disclose product-level revenue for LUMIFY Preservative Free in its public financial reporting. Revenue exposure must therefore be assessed through the broader LUMIFY franchise and the company’s over-the-counter consumer portfolio rather than a separately reported product line [7].

Commercial value is likely concentrated in:

• Premium OTC pricing.
• High retail visibility.
• Repeat use.
• Expansion of the LUMIFY brand into preservative-free formats.
• Retailer shelf differentiation.
• Consumer migration from older vasoconstrictors.
• Cross-selling with artificial tears and ocular-health products.

The preservative-free format can support higher gross margins if package costs remain controlled and the product maintains a significant retail price premium.

How strong is the LUMIFY preservative-free patent estate?

The apparent strength is stronger at the product-system level than at the ingredient level.

Asset	Relative strength
Brimonidine molecule	Low, because the molecule is established
0.025% concentration	Moderate, depending on claim scope and prior art
Borate-buffer formulation	Low to moderate; common excipients limit breadth
Preservative-free presentation	Moderate
Multidose dispensing device	Moderate to high if the device is proprietary
Aseptic manufacturing process	Moderate, especially as trade secret
Trademark and brand	High commercial value, but does not prevent generic substitution
Consumer positioning	Commercially important, not a patent right

A competitor may avoid direct infringement by using the same active ingredient with a different buffer system, a different bottle, or a unit-dose presentation. The practical value of the estate therefore depends on claim breadth, continuation activity, device ownership, and enforcement history.

What is the litigation and settlement status?

No broadly established public litigation or Paragraph IV settlement should be attributed to LUMIFY Preservative Free without a product-specific court docket, FDA listing, or settlement document. The likely legal disputes would involve formulation patents, device patents, trademark claims, and regulatory exclusivity.

The most important litigation scenarios are:

1. A generic sponsor challenges listed formulation patents.
2. A device supplier asserts infringement against a competing preservative-free bottle.
3. Bausch + Lomb challenges trade dress or trademark similarity.
4. A competitor launches after designing around a formulation or package claim.
5. A supplier dispute affects access to a specialized dispensing system.

Key Takeaways

• LUMIFY Preservative Free uses brimonidine tartrate 0.025% in a sterile aqueous ophthalmic formulation.
• Boric acid, sodium borate, and sodium chloride provide the principal buffering and tonicity functions.
• The commercial differentiator is preservative-free delivery, not a new active ingredient.
• Packaging, sterility assurance, drop-size control, and microbial-barrier performance are central to product value.
• Generic risk is high for the active ingredient and common excipients but lower for proprietary multidose delivery systems.
• The strongest potential intellectual-property position covers formulation, packaging, and manufacturing together.
• LUMIFY Preservative Free is not a biosimilar product, and biosimilar competition is not relevant to its market.
• Product-level revenue is not separately disclosed by Bausch + Lomb.
• Licensing opportunities are most attractive in preservative-free multidose devices and validated container-formulation systems.

FAQs About LUMIFY Preservative Free Eye Drops

Is LUMIFY Preservative Free the same as prescription brimonidine?

No. LUMIFY contains brimonidine tartrate 0.025% for temporary ocular redness relief. Prescription brimonidine products generally use different strengths and indications, including treatment of elevated intraocular pressure.

Can a competitor copy the LUMIFY excipients?

A competitor can generally use the same publicly known excipients unless a valid patent claim covers the specific composition, concentration range, process, or product configuration. The competitor must still satisfy FDA requirements for safety, stability, sterility, and labeling.

Does preservative-free LUMIFY require a special bottle?

Yes. The packaging must maintain sterility without relying on a conventional antimicrobial preservative. The package may be single-dose or use a specialized multidose dispensing system.

Is LUMIFY Preservative Free suitable for contact-lens wearers?

Suitability depends on the product labeling and dosing instructions. Contact lenses may need to be removed before administration and reinserted only after the specified interval.

What is the biggest commercial threat to LUMIFY Preservative Free?

The largest threat is a lower-priced brimonidine redness-relief product that matches the active concentration while using a simpler unit-dose or alternative preservative-free package.

References

1. DailyMed. (n.d.). LUMIFY brimonidine tartrate ophthalmic solution, 0.025% labeling. U.S. National Library of Medicine.
2. Bausch + Lomb. (n.d.). LUMIFY redness reliever eye drops product information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards.
5. U.S. Food and Drug Administration. (2009). Container closure systems for packaging human drugs and biologics.
6. U.S. Food and Drug Administration. (2020). Sterile drug products produced by aseptic processing: Current good manufacturing practice.
7. Bausch + Lomb Corporation. (2024). Annual report and Form 10-K. U.S. Securities and Exchange Commission.